U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07561775) titled 'Adebrelimab Plus S-1 for Resected Cholangiocarcinoma' on April 25.
Brief Summary: The goal of this clinical trial is to learn whether adebrelimab combined with S-1 works as an adjuvant treatment for patients with cholangiocarcinoma after curative surgery. It will also learn about the safety of this treatment. The main questions it aims to answer are:
* Does adebrelimab combined with S-1 reduce the risk of cancer recurrence after surgery?
* What side effects do participants experience when receiving this treatment? All participants in this study will receive adebrelimab combined with S-1. There is no comparison group in this study.
...